MASTL

microtubule associated serine/threonine kinase like, the group of AGC family kinases

Basic information

Region (hg38): 10:27154824-27187953

Links

ENSG00000120539NCBI:84930OMIM:608221HGNC:19042Uniprot:Q96GX5AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • autosomal thrombocytopenia with normal platelets (Supportive), mode of inheritance: AD

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Thrombocytopenia 2ADHematologicIndividuals may have bleeding tendency, and precautions (eg, in surgical situations) may be beneficialHematologic10891439; 12890928; 22102272

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the MASTL gene.

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the MASTL gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
6
clinvar
8
clinvar
6
clinvar
20
missense
49
clinvar
13
clinvar
9
clinvar
71
nonsense
2
clinvar
2
start loss
0
frameshift
0
inframe indel
0
splice donor/acceptor (+/-2bp)
1
clinvar
1
splice region
1
2
3
non coding
13
clinvar
7
clinvar
29
clinvar
49
Total 0 0 71 28 44

Variants in MASTL

This is a list of pathogenic ClinVar variants found in the MASTL region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
10-27154826-T-A Thrombocytopenia Uncertain significance (Jun 14, 2016)299772
10-27154859-G-A Thrombocytopenia Uncertain significance (Jun 14, 2016)299773
10-27154946-C-T Thrombocytopenia Benign/Likely benign (Jun 19, 2021)299774
10-27155080-CG-C Thrombocytopenia Uncertain significance (Jun 14, 2016)299775
10-27155082-T-C Thrombocytopenia Uncertain significance (Jun 14, 2016)299776
10-27155173-T-G Thrombocytopenia Uncertain significance (Jun 14, 2016)299777
10-27155187-G-A Thrombocytopenia Uncertain significance (Jun 14, 2016)299778
10-27155201-G-A Thrombocytopenia Uncertain significance (Jun 14, 2016)299779
10-27155228-G-C Thrombocytopenia Benign/Likely benign (Jun 19, 2021)299780
10-27155257-C-T Thrombocytopenia Uncertain significance (Jun 14, 2016)299781
10-27155270-C-T Thrombocytopenia Uncertain significance (Jun 14, 2016)299782
10-27155311-C-CG Thrombocytopenia Likely benign (Jun 14, 2016)299783
10-27155321-T-C Thrombocytopenia Likely benign (Jun 14, 2016)299784
10-27155374-G-A Thrombocytopenia Benign (Jun 19, 2021)299785
10-27155399-C-A not specified • Thrombocytopenia Benign (Jun 19, 2021)262113
10-27155400-T-C not specified • Thrombocytopenia Benign (Jun 19, 2021)262112
10-27155415-T-G not specified • Thrombocytopenia Benign (Jun 19, 2021)262111
10-27155458-C-T not specified Uncertain significance (Jul 11, 2023)2599973
10-27155460-G-C not specified • Thrombocytopenia Benign/Likely benign (Apr 10, 2018)262123
10-27155535-A-C MASTL-related disorder Uncertain significance (Jan 08, 2023)2629970
10-27155536-T-C Thrombocytopenia Uncertain significance (Jan 12, 2018)878999
10-27155649-C-T not specified Benign (Jun 19, 2021)262117
10-27155777-A-T Benign (Jun 19, 2021)1268165
10-27155834-C-A Benign (Jun 19, 2021)1275356
10-27158276-T-C Benign (Jun 20, 2021)1263152

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
MASTLprotein_codingprotein_codingENST00000375940 1232101
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
5.44e-130.79812561801301257480.000517
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.5054284580.9340.00002195839
Missense in Polyphen140165.190.847532187
Synonymous1.371461690.8660.000008781657
Loss of Function1.812536.90.6780.00000180483

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.001290.00129
Ashkenazi Jewish0.00009920.0000992
East Asian0.0002720.000272
Finnish0.002240.00222
European (Non-Finnish)0.0002380.000237
Middle Eastern0.0002720.000272
South Asian0.000.00
Other0.001630.00163

dbNSFP

Source: dbNSFP

Function
FUNCTION: Serine/threonine kinase that plays a key role in M phase by acting as a regulator of mitosis entry and maintenance. Acts by promoting the inactivation of protein phosphatase 2A (PP2A) during M phase: does not directly inhibit PP2A but acts by mediating phosphorylation and subsequent activation of ARPP19 and ENSA at 'Ser-62' and 'Ser-67', respectively. ARPP19 and ENSA are phosphatase inhibitors that specifically inhibit the PPP2R2D (PR55-delta) subunit of PP2A. Inactivation of PP2A during M phase is essential to keep cyclin-B1-CDK1 activity high. Following DNA damage, it is also involved in checkpoint recovery by being inhibited. Phosphorylates histone protein in vitro; however such activity is unsure in vivo. May be involved in megakaryocyte differentiation. {ECO:0000269|PubMed:12890928, ECO:0000269|PubMed:19680222, ECO:0000269|PubMed:19793917, ECO:0000269|PubMed:20538976, ECO:0000269|PubMed:20818157}.;
Disease
DISEASE: Note=Defects in MASTL may play a role in the pathogenesis of thrombocytopenia, a disorder defined by reduced number of platelets in circulating blood, resulting in the potential for increased bleeding and decreased ability for clotting. {ECO:0000269|PubMed:12890928}.;
Pathway
MASTL Facilitates Mitotic Progression;Mitotic Prophase;M Phase;Cell Cycle;Cell Cycle, Mitotic (Consensus)

Recessive Scores

pRec
0.111

Intolerance Scores

loftool
0.984
rvis_EVS
1.14
rvis_percentile_EVS
92.33

Haploinsufficiency Scores

pHI
0.296
hipred
N
hipred_score
0.170
ghis
0.548

Essentials

essential_gene_CRISPR
E
essential_gene_CRISPR2
E
essential_gene_gene_trap
E
gene_indispensability_pred
N
gene_indispensability_score
0.0182

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Mastl
Phenotype
embryo phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); cellular phenotype;

Zebrafish Information Network

Gene name
mastl
Affected structure
thrombocyte
Phenotype tag
abnormal
Phenotype quality
decreased amount

Gene ontology

Biological process
G2/M transition of mitotic cell cycle;mitotic cell cycle;cellular response to DNA damage stimulus;female meiosis II;peptidyl-serine phosphorylation;negative regulation of phosphoprotein phosphatase activity;intracellular signal transduction;cell division;regulation of cell cycle;positive regulation of ubiquitin protein ligase activity
Cellular component
nucleus;nucleoplasm;cytoplasm;centrosome;cleavage furrow
Molecular function
protein serine/threonine kinase activity;ATP binding;kinase activity;protein phosphatase 2A binding